Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Total Current Liabilities
Gensight Biologics SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Total Current Liabilities
€16.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Current Liabilities
€109.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Total Current Liabilities
€38.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
12%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Liabilities
€36.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
10%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Liabilities
€48.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Current Liabilities
€54.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
19%
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Total Current Liabilities?
Total Current Liabilities
16.9m
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Total Current Liabilities amounts to 16.9m EUR.
What is Gensight Biologics SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
14%
Over the last year, the Total Current Liabilities growth was -45%. The average annual Total Current Liabilities growth rates for Gensight Biologics SA have been -1% over the past three years , 14% over the past five years .
You don't have any saved screeners yet